Michael Healy-Rae (Kerry, Independent)
Link to this: Individually | In context | Oireachtas source

395. To ask the Minister for Health if he will address a matter in respect of a person (details supplied) regarding funding; and if he will make a statement on the matter. [17729/18]

Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

Since August 2014 Brentuximab vedotin has been approved and funded by the HSE for use in relapsed or refractory CD30+ Hodgkin Lymphoma following Autologous Stem Cell Transplantation (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option as well as for use in relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

A pricing application is ongoing in relation to the use of Brentuximab vedotin for CD30+ cutaneous T-cell lymphoma (CTCL). This application is being considered in line with the criteria set out in the Health (Pricing and Supply of Medical Goods) Act 2013.

The European Medicines Agency to date has not approved any other indication (use) in Europe. The treatment of Angioimmunoblastic T-cell lymphoma is not included in the currently reimbursed indications.